A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis

NCT04594707 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

117

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated by Sponsor as the futility analysis outcome indicated that the study was unlikely to meet the predefined primary objective of the study. No new safety concerns were identified.

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: PRM-151 (Zinpentraxin Alfa)

Sponsor

Hoffmann-La Roche